Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered public markets through a SPAC merger with Ignyte Acquisition Corp, whose blank-check vehicle completed its IPO in 2021 under sponsor Ignyte Acquisition Sponsor LLC. The company focuses on oncology and rare disease therapeutics, operating within the healthcare and life sciences sector. The 10-Q quarterly report filed on May 19, 2022, under accession number 0001206774-22-001427, reflects the company's reporting obligations as it progressed through its de-SPAC process and subsequent public company status. Peak Bio's pipeline includes antibody-drug conjugate programs targeting unmet clinical needs. For the full filing history, deal terms, and SPAC sponsor details on PKBO and thousands of other transactions, sign up for complete data access at SpacDesk.